These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1714748)

  • 1. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory.
    Mannhalter JW; Pum M; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
    AIDS Res Hum Retroviruses; 1991 May; 7(5):485-93. PubMed ID: 1714748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N; Eder G; Dorner F
    Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells.
    Mannhalter JW; Fischer MB; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
    J Infect Dis; 1995 Feb; 171(2):437-40. PubMed ID: 7844384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
    Nixon A; Zaghouani H; Penney CL; Lacroix M; Dionne G; Anderson SA; Kennedy RC; Bona CA
    Viral Immunol; 1992; 5(2):141-50. PubMed ID: 1616585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
    Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I- and class II-restricted T cells: not all T cells can respond to whole molecule stimulation.
    Moore RL; Fox BS
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):51-9. PubMed ID: 7678972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates.
    Hosmalin A; Nara PL; Zweig M; Lerche NW; Cease KB; Gard EA; Markham PD; Putney SD; Daniel MD; Desrosiers RC
    J Immunol; 1991 Mar; 146(5):1667-73. PubMed ID: 1704401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production in rabbits of high levels of anti-HIV-1 gp160 antibodies.
    Relyveld E; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):389-93. PubMed ID: 7580832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
    Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
    N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current approaches to vaccination against human immunodeficiency viruses.
    Gluckman JC; Yagello M; Bahraoui E; Girard M
    Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
    [No Abstract]   [Full Text] [Related]  

  • 12. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
    Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates.
    Newman MJ; Wu JY; Coughlin RT; Murphy CI; Seals JR; Wyand MS; Kensil CR
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1413-8. PubMed ID: 1466970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
    Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
    AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
    Sjölander S; Bolmstedt A; Akerblom L; Horal P; Olofsson S; Morein B; Sjölander A
    Virology; 1996 Jan; 215(2):124-33. PubMed ID: 8560759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.
    Bergmann CC; Tong L; Cua RV; Sensintaffar JL; Stohlman SA
    J Immunol; 1994 Jun; 152(12):5603-12. PubMed ID: 7515908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
    Klaniecki J; Dykers T; Travis B; Schmitt R; Wain M; Watson A; Sridhar P; McClure J; Morein B; Ulrich JT
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):791-8. PubMed ID: 1742074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
    Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
    J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
    Bona C; Nixon A; Kennedy R; Zaghouani H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1377. PubMed ID: 1466959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.